Capivasertib Plus Fulvestrant Doubles Progression-Free Survival in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer – The ASCO Post

The combination of capivasertib, an AKT pathway inhibitor, plus fulvestrant, an estrogen receptor antagonist, significantly improved progression-free survival compared with fulvestrant alone in patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to results of the phase III CAPItello-291 trial presented at the 2022 San Antonio Breast Cancer Symposium. This…

Read the full article here

Source: ascopost.com

Categories: Hem/Onc News and Journals, Latest Headlines

Tags: bcsm, BreastCancer, oncology, SABCS22

Tweets with this article

The ASCO Post

Capivasertib Plus Fulvestrant Doubles Progression-Free Survival in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer https://t.co/Ef1eMalk2p #bcsm #breastcancer #oncology #SABCS22 @SABCSSanAntonio

Related Articles

Illuminating a Potential Culprit in Melanoma Treatment Resistance

Researchers may have uncovered the mechanisms behind the development of targeted therapy resistance in melanoma.

The ASCO Post April 16, 2024

Exploring Geriatric Assessment Effectiveness: Insights From the 2023 International Society of Geriatric Oncology Conference

Recent findings from studies presented at the 2023 International Society of Geriatric Oncology Annual Conference shed light on the effectiveness and cost-effectiveness of geriatric assessment…

The ASCO Post April 16, 2024

Novel Urine Biomarker Test May Reduce Unnecessary Cystoscopies in Patients With Bladder Cancer

A novel urine biomarker test may help reduce the number of cystoscopies necessary in high-risk patients with bladder cancer, according to findings presented at the…

Santhosh Ambika April 14, 2024

Lung Cancer Screening Eligibility: Effect of Using History vs Pack-Year History of Smoking

Researchers found that use of a smoking history of ≥ 20 years rather than the current 2021 U.S. Preventive Services Task Force guideline of ≥…

The ASCO Post April 13, 2024

B-Cell Non-Hodgkin Lymphoma: Extended Follow-up With Mosunetuzumab

Extended follow-up of the dose-escalation phase of a phase I/II trial showed that the CD20 x CD3 T-cell–engaging bispecific antibody mosunetuzumab-axgb—given as an off-the-shelf fixed-duration…

The ASCO Post April 13, 2024

Novel Urine Biomarker Test May Reduce Unnecessary Cystoscopies in Patients With Bladder Cancer

A novel urine biomarker test may help reduce the number of cystoscopies necessary in high-risk patients with bladder cancer, according to findings presented at the…

Santhosh Ambika April 13, 2024

Longer Interval May Be Safe for Prostate Cancer Screening in Low-Risk Patients

Is undergoing a prostate-specific antigen blood test every 5 years an adequate screening interval for men at low risk of the disease? A research team…

The ASCO Post April 13, 2024

The Lancet Commission on Prostate Cancer: Strategies to Prepare for Predicted Increases in Disease Burden by 2040

Investigators have projected impending increases in the incidence and mortality of prostate cancer—especially among individuals in low- and middle-income countries—and proposed new strategies to impro…

The ASCO Post April 13, 2024

Blood-Based Machine-Learning Assay May Noninvasively Detect Early Ovarian Cancer

A blood-based machine learning assay that combines cell-free DNA fragmentomes and protein biomarkers was able to differentiate patients with ovarian cancer from healthy controls at…

The ASCO Post April 12, 2024

Effect of Virtually Delivered CBT for Insomnia on Cancer-Related Cognitive Impairment

In a Canadian study, researchers found that virtually delivered cognitive behavioral therapy (CBT) for insomnia in cancer survivors improved perceived cancer-related cognitive impairment vs waiting…

The ASCO Post April 12, 2024